SRTAHealthcare · Medical Care FacilitiesThe 4 Wall Street analysts covering Strata Critical Medical, Inc. hold a median 12-month price target of $8.75 — +40.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 46 of 100 as at 22 Aug 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Strata Critical Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (80): The shares have been drifting up relative to others.
Accruals (18): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on SRTA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +40.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 25 Mar 2026 | B. Riley Securities | Initiates | Buy | $8.00 |
| 25 Mar 2026 | Craig-Hallum | Initiates | Buy | $8.00 |
| 2 Dec 2025 | Lake Street | Assumes | Buy | $8.00 |
| 17 Sept 2025 | Lake Street | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SRTA appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 53% of US stocks
Cheaper than 51% of US stocks
Cheaper than 47% of US stocks
Cheaper than 3% of US stocks
Higher than 89% of US stocks
Higher than 39% of US stocks
Higher than 23% of US stocks
Higher than 26% of US stocks
Higher than 78% of US stocks
Higher than 36% of US stocks
Higher than 37% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Strata Critical Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks reports that Strata Critical Medical, Inc. (SRTA) shares have started gaining and, based on solid earnings estimate revisions, might continue moving higher in the near term.
Why it matters — A SRTA watcher would care because the improved earnings estimates point to a possible continuing upward trend in the stock.
The consensus price target for Strata Critical Medical, Inc. (SRTA) hints at 60% upside potential. While research shows this measure is not highly effective, an upward trend in earnings estimate revisions suggests the stock could see near-term upside.
Why it matters — SRTA watchers would note the analyst consensus price target and the upward trend in earnings estimate revisions as indicators of possible near-term stock movement.
Seeking Alpha published the Q2 2026 earnings call transcript for Strata Critical Medical, Inc. (SRTA). The item identifies the transcript as the source document covering the company's quarterly earnings call.
Why it matters — A SRTA watcher would care because the transcript provides the full record of management's commentary from the Q2 2026 earnings call.
Strata Critical Medical reported Q2 2026 results with revenue rising 60.7% year-over-year to $72.5 million, while posting a $10.5 million net loss from continuing operations, $7.9 million in adjusted EBITDA, and $5.7 million in operating cash flow. During the quarter the company completed bolt-on acquisitions of Louisville Perfusion Services, Heart and Lung Transplant National Recovery Program, and Ohio Valley Perfusion Associates, and signed an agreement to take over Statline's Transplant Center Organ Placement customer relationships on a rolling basis.
Why it matters — SRTA watchers would care because the strong revenue growth, including a 23.8% increase in Transplant Clinical revenue, plus the new acquisitions and Statline agreement signal continued expansion of the company's organ placement and transplant services.
The 4 Wall Street analysts covering Strata Critical Medical, Inc. have a median 12-month price target of $8.75, with estimates ranging from $8 to $13. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Strata Critical Medical, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Strata Critical Medical, Inc. 46 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Strata Critical Medical, Inc. ranks 46 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (80 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +40.4% from the last close, and Ticker Nerd's factor model ranks Strata Critical Medical, Inc. 46 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Strata Critical Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SRTA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $13 over the next 12 months.
Strata Critical Medical, Inc. returned +46.9% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Strata Critical Medical, Inc. provides time-critical logistics and medical services to the healthcare industry in the United States.
The most recent item we track (Zacks Investment Research, 6 Aug 2026): "Can Strata Critical Medical, Inc. (SRTA) Run Higher on Rising Earnings Estimates?". Zacks reports that Strata Critical Medical, Inc. (SRTA) shares have started gaining and, based on solid earnings estimate revisions, might continue moving higher in the near term.
Strata Critical Medical, Inc. provides time-critical logistics and medical services to the healthcare industry in the United States. It operates in two segments, Logistics and Clinical. The company offers logistics services, such as air and ground transportation for human organs, transplant teams, and related medical materials and organ placement services; transplant clinical services, including organ recovery procedures, normothermic regional perfusion, and preservation services. It also provides other clinical services comprising cardiac perfusion services, blood management and autotransfusion services, extracorporeal membrane oxygenation services, perfusion staffing, and equipment rentals. The company was formerly known as Blade Air Mobility, Inc. and changed its name to Strata Critical Medical, Inc. in August 2025. The company was founded in 2014 and is headquartered in New York, New York.
CEO Ms. Melissa M. Tomkiel J.D. · 327 employees · United States · https://www.stratacritical.com